---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116799"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:14:01.032926+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioXcel Q3 net loss $41.8M; revenue $137K; IGALMI launch progress with 70-rep sales force by Dec 1

## Summary
- Net loss of $41.8M for Q3 2022 vs $26.8M loss in Q3 2021; revenue $137K from early product trials.
- Cash and equivalents $232.3M; operating cash used $31.5M in quarter.
- IGALMI commercial: signed largest GPO covering ~50% target beds; expanding sales force to 70 reps by Dec 1 covering 1,700 hospitals.
- Pipeline: TRANQUILITY II and SERENITY III top-line data expected 1H 2023 for agitation indications.
- Phase 1 MDD program completed multiple daily dosing cohorts; top-line results expected 1H 2023.

## SEC filing metadata
- accession: 0001104659-22-116799
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/0001104659-22-116799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/tm2230135d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116799
- JSON: https://secwatch.observer/filing/0001104659-22-116799.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116799.txt

## Key facts
- Earnings Releases
  BioXcel Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on key strategic initiatives.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/0001104659-22-116799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.